The Healthy and At-Risk Populations program (HARP) has 34 core members representing four schools and 13 departments in total. During the current funding year, cancer-related funding for this program totaled $20.8M in total costs. Of this amount, peer-reviewed funding totaled $13.5M in total costs, including $3.4M from the National Cancer Institute. As with other programs, JCCC fosters a number of interactive activities and shared resources that support investigators in HARP. During the current grant cycle, funds from the JCCC in the form of the CCSG Developmental Funds, institutional support and philanthropic gifts to HARP total $2,043,085. These funds supported seed grants, program area leadership support, as well as the annual disparities symposium hosted by HARP in the community. The HARP program is highly interactive, with 15% of its publications reflecting intra-programmatic efforts and 11 % reporting inter-programmatic collaborations. 178 (28%) appeared in high-impact journals. Accruals to prevention trials totaled 1,186, screening 1,021, early detection/diagnostic 1,151, epidemiologic/obs/outcome 1,426, correlative 113. The goals of the HARP are to advance understanding of cancer risk and protective factors and to identify strategies to make the latest cancer prevention knowledge and technologies accessible to the population at large. HARP research spans four broad focus areas: 1. cancer risk and protective factors/etiology, 2. primary prevention, 3. screening/early detection, 4. infrastructure projects supporting community engagement. Two major themes characterize the research of this program: cancer disparities and translational research (mainly T3 and T4). These themes are not mutually exclusive, and in fact most projects in the program incorporate both. Our cancer disparities research focuses on cancer prevention and control interventions to mitigate disparities in low-income, ethnic minority and other socially and medically underserved populations in Los Angeles and beyond and has brought recognition to UCLA as one of the premier cancer disparities research programs in the nation.

Public Health Relevance

The Healthy and At-Risk Populations Program (HARP) has 34 core members conducting work within four focus areas: 1. cancer risk and protective factors/etiology, 2. primary prevention, 3. screening/early detection, 4. infrastructure projects to support community engagement. Two major themes, which cut across the four focus areas, characterize the research in HARP: cancer disparities and translational research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016042-39
Application #
8635438
Study Section
Subcommittee G - Education (NCI)
Project Start
1996-12-01
Project End
2018-11-30
Budget Start
2014-03-07
Budget End
2014-11-30
Support Year
39
Fiscal Year
2014
Total Cost
$32,232
Indirect Cost
Name
University of California Los Angeles
Department
Type
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Glenn, Beth A; Hamilton, Ann S; Nonzee, Narissa J et al. (2018) Obesity, physical activity, and dietary behaviors in an ethnically-diverse sample of cancer survivors with early onset disease. J Psychosoc Oncol 36:418-436
Tsai, Wen-Ting K; Wu, Anna M (2018) Aligning physics and physiology: Engineering antibodies for radionuclide delivery. J Labelled Comp Radiopharm 61:693-714
Lisova, Ksenia; Sergeev, Maxim; Evans-Axelsson, Susan et al. (2018) Microscale radiosynthesis, preclinical imaging and dosimetry study of [18F]AMBF3-TATE: A potential PET tracer for clinical imaging of somatostatin receptors. Nucl Med Biol 61:36-44
Chang, Yu-Ling; Rossetti, Maura; Vlamakis, Hera et al. (2018) A screen of Crohn's disease-associated microbial metabolites identifies ascorbate as a novel metabolic inhibitor of activated human T cells. Mucosal Immunol :
Kiertscher, Sylvia M; Gangalum, Pallavi R; Ibrahim, Grace et al. (2018) A Prospective Study of Humoral and Cellular Immune Responses to Hepatitis B Vaccination in Habitual Marijuana Smokers. J Neuroimmune Pharmacol 13:219-229
Jia, Qingmei; Bowen, Richard; Dillon, Barbara Jane et al. (2018) Single vector platform vaccine protects against lethal respiratory challenge with Tier 1 select agents of anthrax, plague, and tularemia. Sci Rep 8:7009
Van, Christina; Condro, Michael C; Lov, Kenny et al. (2018) PACAP/PAC1 Regulation of Inflammation via Catecholaminergic Neurons in a Model of Multiple Sclerosis. J Mol Neurosci :
Leoh, Lai Sum; Kim, Yoon Kyung; Candelaria, Pierre V et al. (2018) Efficacy and Mechanism of Antitumor Activity of an Antibody Targeting Transferrin Receptor 1 in Mouse Models of Human Multiple Myeloma. J Immunol 200:3485-3494
Hicks, Michael R; Hiserodt, Julia; Paras, Katrina et al. (2018) ERBB3 and NGFR mark a distinct skeletal muscle progenitor cell in human development and hPSCs. Nat Cell Biol 20:46-57
Tsang, Eric J; Wu, Benjamin; Zuk, Patricia (2018) MAPK signaling has stage-dependent osteogenic effects on human adipose-derived stem cells in vitro. Connect Tissue Res 59:129-146

Showing the most recent 10 out of 767 publications